Apr. 28, 2014, 8:27 AM
- Forest Labs (FRX) acquires Furiex Pharmaceuticals (FURX) for $95/share ($1.1B) in cash and up to $30/share in a Contingent Value Right (CVR) payable on the regulatory approval of eluxadoline.
- Forest will divest Furiex's royalties on alogliptin and Priligy to Royalty Pharma for $415M which will reduce its purchase price by ~$315M (after tax).
- Furiex shares are up 26% premarket on robust volume.
Feb. 19, 2014, 12:11 PM| Feb. 19, 2014, 12:11 PM | Comment!
Furiex Pharmaceuticals, Inc. is a drug development collaborate company that collaborates with pharmaceutical and biotechnology companies to increase the value of their drug candidates by applying an accelerated approach to drug development.
Other News & PR